Pharmaceuticals & Therapeutics

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

Brazilian aerospace giant Embraer shatters financial records and builds its largest-ever order book, signaling a robust recovery in global aviation.

Scientists find herpes melts the inside of our cells to replicate faster, a discovery that could revolutionize treatments for a host of viral diseases.

BioRestorative Therapies is leveraging its clinical-grade regenerative medicine to disrupt the aesthetics industry. Can science beat marketing?

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

Investors watch closely as CytoSorbents balances a push for profitability with high-stakes regulatory hurdles for its life-saving blood purification tech.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

K-beauty giant COSRX and fashion house Courrèges reunite at PFW, unveiling an exclusive kit that signals a new era for luxury skincare on the runway.

OmniAb reported declining revenue and a wider net loss for 2025, even as it launched its revolutionary OmniUltra platform and its partners' drugs advance.

The new iPSC-derived sensory neurons offer a reproducible human model, aiming to fix the broken pipeline of pain research and accelerate new analgesics.

A new, smaller implant for back surgery promises easier procedures for surgeons and lasting relief for patients by tackling the risk of reherniation.

Cordis presents pivotal 12-month data for its innovative SELUTION SLR drug-eluting balloon, a device that could change how doctors treat clogged arteries.

In a booming aesthetics market, one company is enlisting elite surgeons to architect the future of recovery, aiming to close a critical gap in patient care.

A national network is expanding its specialized centers, offering a new model of lifetime care to combat years of diagnostic delays and dismissed pain.

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

Amid a volatile market, Ligand presents its sustainable growth blueprint, powered by royalties and partnerships, to top investors this March.

As a deadly superbug spreads, BioVersys's BV100 enters late-stage trials, backed by promising data and a novel scientific approach to combat resistance.

The biotech plans to separate its R&D pipeline from its booming royalty assets, creating two public companies and winning applause from Wall Street.

With record 2025 revenue and a dominant hold on the gene therapy market, Cryoport's strategic investments pave a path toward profitability.